Startups Flock to Turn Young Blood Into an Elixir of Youth

While much work remains to be done on how this regenerative process actually works, Stanford’s parabiosis studies have since inspired the creation of a handful of ambitious startups aimed at producing similarly dramatic effects in humans. Today, the latest young-blood medicine-maker, Elevian, emerged from stealth with $5.5 million from investors including Peter Diamandis, one of the more prominent faces in the Silicon Valley "death disruption" scene.

Megan Molteni

https://www.wired.com/story/startups-flock-to-turn-young-blood-into-an-elixir-of-youth/